Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone in Conduct Disorder with Mental Retardation
NCT00250354Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 1997
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in conduct disorder (CD), oppositional defiant disorder (ODD) and Disruptive behavior disorders (DBD) comparing Risperidone with Placebo (2 arms). Primary endpoint: Change in the Conduct Problem subscale of the Nisonger Child Behavior Rating Form at 6 weeks. Started Sep 1997; status: completed.
02
Drugs
risperidone
03
Conditions
conduct disorder (CD)oppositional defiant disorder (ODD)Disruptive behavior disorders (DBD)
Beyond the preview
Go deeper on NCT00250354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250354.